FDA, Experts Debate Minimal Residual Disease as Endpoint

The first readily apparent conclusion from Wednesday's FDA workshop on the use of minimal residual disease (MRD) as a surrogate endpoint in acute lymphoblastic leukemia (ALL) is that technical implementation issues continue to lag and could stifle the obvious clinical interest in developing such efficacy biomarkers.